Madrigal Pharmaceuticals (MDGL) to Release Earnings on Tuesday

Madrigal Pharmaceuticals (NASDAQ:MDGL) is expected to post its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($2.01) per share and revenue of $244.3320 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, beating analysts’ consensus estimates of ($3.48) by $1.58. The company had revenue of $212.80 million for the quarter, compared to analysts’ expectations of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. Madrigal Pharmaceuticals’s revenue was up 1357.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($7.10) EPS. On average, analysts expect Madrigal Pharmaceuticals to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL stock opened at $418.90 on Friday. The stock has a market capitalization of $9.30 billion, a P/E ratio of -32.60 and a beta of -1.02. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17. The firm’s 50 day moving average is $433.67 and its 200 day moving average is $352.46. Madrigal Pharmaceuticals has a 12 month low of $238.04 and a 12 month high of $463.63.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Piper Sandler upped their price target on shares of Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 26th. B. Riley upped their target price on shares of Madrigal Pharmaceuticals from $460.00 to $560.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 8th. Finally, HC Wainwright initiated coverage on shares of Madrigal Pharmaceuticals in a report on Thursday, September 4th. They set a “buy” rating and a $500.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $532.70.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, General Counsel Shannon T. Kelley sold 1,304 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $367.81, for a total value of $479,624.24. Following the transaction, the general counsel owned 9,173 shares of the company’s stock, valued at $3,373,921.13. This represents a 12.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Paul A. Friedman sold 129,172 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $370.24, for a total transaction of $47,824,641.28. Following the completion of the transaction, the director directly owned 187,164 shares in the company, valued at $69,295,599.36. The trade was a 40.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have purchased 165,683 shares of company stock worth $61,921,142 and have sold 248,642 shares worth $91,388,103. Insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Orion Porfolio Solutions LLC increased its holdings in shares of Madrigal Pharmaceuticals by 1.3% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 3,638 shares of the biopharmaceutical company’s stock worth $1,101,000 after buying an additional 47 shares during the last quarter. Kestra Investment Management LLC bought a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter worth $85,000. The Manufacturers Life Insurance Company increased its holdings in shares of Madrigal Pharmaceuticals by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company’s stock worth $7,087,000 after buying an additional 471 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Madrigal Pharmaceuticals by 70.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,851 shares of the biopharmaceutical company’s stock worth $560,000 after buying an additional 764 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter worth $309,000. Institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.